PubMed Health⌕ Search

Biomedical subjects

S Kugler

Publications and source records attributed to S Kugler.

11 recordsLinked to original sources
PubMed2005

Photoinduced volume changes in amorphous selenium.

We have modeled the photoinduced volume change in amorphous selenium. After photon absorption, we treated the excited electron and hole independently within the framework of the tight-binding formalism. We found covalent bond breaking in amorphous networks with photoinduced excited electrons, whereas excited holes contribute to the formation of interchain bonds. We also observed a correlated volume change of the amorphous samples. Our results provide a new and universal description, which can simultaneously explain the photoinduced volume expansion and shrinkage. This model is supported by very recent in situ surface height measurements for amorphous selenium.

Journal Article↗
PubMed2004

Mechanical characterisation of a bone defect model filled with ceramic cements.

Ceramic bone substitute materials are often used to fill defects in comminuted articular fractures. In an in vivo study [1], calcium phosphate cements have been injected into highly loaded slot defects in the proximal tibial metaphysis. During healing, cracks were formed mostly in the proximal anterior aspect of the implanted cement and wedge-like gaps formed between the tibial plateau and the cement. Mechanical ex vivo tests were done to investigate the mechanical competence of the bone cement in such a defect situation. Entirely filled defects were loaded with up to 4.5 kN until they failed. Cyclic loading of the proximal tibiae caused micro fragmentation of the cement after 1000 cycles at 1.5-2.0 kN load. This aspect was comparable to cement fragmentation observed in vivo. Large defects in highly loaded areas should therefore additionally be stabilised with metallic implants. The ceramic cement can only be used as a filler material, which can be replaced by new bone upon resorption.

Animals↗
PubMed2000

Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces clinical, biochemical, and neuropathological changes reminiscent of those occurring in idiopathic Parkinson's disease (PD). Here we show that a peptide caspase inhibitor, N-benzyloxy-carbonyl-val-ala-asp-fluoromethyl ketone, or adenoviral gene transfer (AdV) of a protein caspase inhibitor, X-chromosome-linked inhibitor of apoptosis (XIAP), prevent cell death of dopaminergic substantia nigra pars compacta (SNpc) neurons induced by MPTP or its active metabolite 1-methyl-4-phenylpyridinium in vitro and in vivo. Because the MPTP-induced decrease in striatal concentrations of dopamine and its metabolites does not differ between AdV-XIAP- and control vector-treated mice, this protection is not associated with a preservation of nigrostriatal terminals. In contrast, the combination of adenoviral gene transfer of XIAP and of the glial cell line-derived neurotrophic factor to the striatum provides synergistic effects, rescuing dopaminergic SNpc neurons from cell death and maintaining their nigrostriatal terminals. These data suggest that a combination of a caspase inhibitor, which blocks death, and a neurotrophic factor, which promotes the specific function of the rescued neurons, may be a promising strategy for the treatment of PD.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗
PubMed2000

Dopaminergic therapy in children with restless legs/periodic limb movements in sleep and ADHD. Dopaminergic Therapy Study Group.

The long-term effects of monotherapy with levodopa or the dopamine agonist pergolide on the motor/sensory, behavioral, and cognitive variables in seven children with restless legs syndrome/periodic limb movements in sleep (RLS/PLMS) and attention-deficit-hyperactivity disorder (ADHD) were investigated. Five of the seven children had previously been treated with stimulants that had either been determined to be ineffective or to have intolerable side effects. Dopaminergic therapy improved the symptoms of RLS and reduced the number of PLMS per hour of sleep (P = 0.018) and associated arousals (P = 0.042) for the entire group. After treatment, three children no longer met the criteria for ADHD, and three reverted to normal on the Test of Variable Attention. ADHD improved in all seven as measured by the Connors parent rating scale (P<0.04) and the Child Behavior Checklist (P<0.05). A significant improvement also occurred in the visual, but not verbal, memory scores on the Wide Range Assessment of Memory and Learning (P<0.001). Five of seven children continue on dopaminergic therapy 3 years after treatment initiation, with good response. We postulate that the improvement in ADHD may be the result of the amelioration of RLS/PLMS and its associated sleep disturbance. Alternatively, ADHD and RLS/PLMS may share a common dopaminergic deficit.

Adolescent↗
PubMed1993

Abnormal cranial magnetic resonance imaging scans in sickle-cell disease. Neurological correlates and clinical implications.

OBJECTIVE: Eight asymptomatic patients with sickle-cell disease (SCD) with magnetic resonance imaging (MRI) abnormalities consistent with cerebral infarcts (group 1) and eight asymptomatic patients with SCD with normal MRI scans (group 2) were followed up to assess the neurological correlates and the clinical outcome. DESIGN: Patients in the two cohorts underwent clinical evaluations and xenon 133 regional cerebral blood flow (rCBF) studies within 1 month of the entry MRI. This study sequence was repeated up to 5 years later. Neuropsychological studies also were performed in six group 1 patients and eight group 2 patients at the end of the study. SETTING: The patients were recruited from the Comprehensive Sickle Cell Center at Columbia University, New York, NY. PATIENTS: All patients had SCD, hemoglobin SS, and normal findings on clinical evaluation at entry. The group 1 cohort had clinically silent MRI abnormalities consistent with cerebral infarction. The group 2 cohort was age matched to group 1 and had normal MRI studies. INTERVENTIONS: None. MAIN OUTCOME MEASURE: The natural history of MRI abnormalities and the neurological correlates were assessed to determine the predictive value of subclinical MRI lesions as a risk factor for clinically apparent stroke. RESULTS: The mean duration of MRI follow-up was 3.7 years. In group 1, four patients (50%) demonstrated progressive MRI abnormalities and three patients (38%) became clinically symptomatic. In group 2, findings for all patients remained normal on clinical and radiological examination. Both groups had markedly elevated rCBF values. Individual rCBF differences correlated with the specific MRI abnormalities. The psychometric study results were similar in the two cohorts. Eighty-three percent of group 1 and 88% of group 2 patients had defective scores in one or more areas of cognitive functioning. Three patients met cognitive criteria for dementia. CONCLUSIONS: Cranial MRI abnormalities have important prognostic implications even when detected in clinically asymptomatic patients. Cognitive abnormalities exist in patients with SCD even in the absence of MRI abnormalities or clinical stroke.

Adolescent↗